GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (NAS:BNGO) » Definitions » Equity-to-Asset

Bionano Genomics (Bionano Genomics) Equity-to-Asset : 0.52 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bionano Genomics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bionano Genomics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $82.77 Mil. Bionano Genomics's Total Assets for the quarter that ended in Mar. 2024 was $158.00 Mil. Therefore, Bionano Genomics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.52.

The historical rank and industry rank for Bionano Genomics's Equity-to-Asset or its related term are showing as below:

BNGO' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.95   Med: 0.5   Max: 0.97
Current: 0.52

During the past 8 years, the highest Equity to Asset Ratio of Bionano Genomics was 0.97. The lowest was -4.95. And the median was 0.50.

BNGO's Equity-to-Asset is ranked worse than
65.6% of 872 companies
in the Medical Devices & Instruments industry
Industry Median: 0.645 vs BNGO: 0.52

Bionano Genomics Equity-to-Asset Historical Data

The historical data trend for Bionano Genomics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Equity-to-Asset Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.12 0.58 0.89 0.81 0.45

Bionano Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.79 0.65 0.45 0.52

Competitive Comparison of Bionano Genomics's Equity-to-Asset

For the Medical Instruments & Supplies subindustry, Bionano Genomics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionano Genomics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bionano Genomics's Equity-to-Asset falls into.



Bionano Genomics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bionano Genomics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=96.157/214.404
=0.45

Bionano Genomics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=82.771/157.995
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionano Genomics  (NAS:BNGO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Bionano Genomics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionano Genomics (Bionano Genomics) Business Description

Traded in Other Exchanges
Address
9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.
Executives
Gulsen Kama officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Hannah Mamuszka director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
R. Erik Holmlin director, officer: President and CEO 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Christopher P. Stewart officer: Chief Financial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Jonathan V. Dixon officer: General Counsel C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Yvonne Linney director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121
Aleksandar Rajkovic director 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Vincent Jung-fai Wong director C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Soheil Shams officer: Chief Informatics Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Richard Shippy officer: Chief Business Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Robert J Priar officer: Chief Commercial Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Alka Chaubey officer: Chief Medical Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Heather Adams officer: Chief Administrative Officer C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011